MENTIONING THE PRESTWICK CHEMICAL LIBRARY®

400+ publications MENTIONING THE PRESTWICK CHEMICAL LIBRARY®

  1. Yousfi, H., Ranque, S., Cassagne, C., Rolain, J. M. & Bittar, F. Identification of repositionable drugs with novel antimycotic activity by screening the Prestwick Chemical Library against emerging invasive moulds. J. Glob. Antimicrob. Resist. 21, 314–317 (2020).
  2. Montanuy, H. et al. High content drug screening for Fanconi anemia therapeutics. Orphanet J. Rare Dis. 15, 1–9 (2020).
  3. Konieczny, P. & Artero, R. Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA. FASEB J. 34, 3021–3036 (2020).
  4. Soleilhac, E. et al. Quantitative Automated Assays in Living Cells to Screen for Inhibitors of Hemichannel Function. SLAS Discov. (2020). doi:10.1177/2472555220954388
  5. Foerster, S. et al. The first wide-scale drug repurposing screen using the Prestwick Chemical Library (1200 bioactive molecules) against Neisseria gonorrhoeae identifies high in vitro activity of auranofin and many additional drugs. Apmis 128, 242–250 (2020).
  6. Howard, C. M., Estrada, M., Terrero, D., Tiwari, A. K. & Raman, D. Identification of cardiac glycosides as novel inhibitors of eif4a1-mediated translation in triple-negative breast cancer cells. Cancers (Basel). 12, 1–18 (2020).
  7. Lesire, L. et al. High-Throughput Image-Based Aggresome Quantification. SLAS Discov. 1–9 (2020). doi:10.1177/2472555220919708
  8. Touret, F. et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. bioRxiv 2020.04.03.023846 (2020). doi:10.1101/2020.04.03.023846
  9. Roy, B. et al. An Unbiased Drug Screen for Seizure Suppressors in Duplication 15q Syndrome Reveals 5-HT1A and Dopamine Pathway Activation as Potential Therapies. Biol. Psychiatry 1–12 (2020). doi:10.1016/j.biopsych.2020.03.021
  10. Kanvatirth, P., Jeeves, R. E., Bacon, J., Besra, G. S. & Alderwick, L. J. Utilisation of the Prestwick Chemical Library to identify drugs that inhibit the growth of mycobacteria. PLoS One 14, (2019).
  11. Martínez, A. L. et al. A New Model of Sensorial Neuron-Like Cells for HTS of Novel Analgesics for Neuropathic Pain. SLAS Discov. 24, 158–168 (2019).
  12. Zhang, S., Jain, M., Fleites, L. A., Rayside, P. A. & Gabriel, D. W. Identification and characterization of menadione and benzethonium chloride as potential treatments of Pierce’s disease of grapevines. Phytopathology 109, 233–239 (2019).
  13. Kang, H. J. et al. Guanabenz acetate induces endoplasmic reticulum stress-related cell death in hepatocellular carcinoma cells. J. Pathol. Transl. Med. 53, 94–103 (2019).
  14. Thieulent, C. J. et al. Screening and evaluation of antiviral compounds against Equid alpha-herpesviruses using an impedance-based cellular assay. Virology 526, 105–116 (2019).
  15. Alexandre, T. et al. First-in-class allosteric inhibitors of bacterial IMPDHs. Eur. J. Med. Chem. 167, 124–132 (2019).
  16. Campos, A. I. & Zampieri, M. Metabolomics-Driven Exploration of the Chemical Drug Space to Predict Combination Antimicrobial Therapies. Mol. Cell 74, 1291-1303.e6 (2019).
  17. De Oliveira, H. C. et al. Identification of Off-Patent Compounds That Present Antifungal Activity against the Emerging Fungal Pathogen Candida auris. Front. Cell. Infect. Microbiol. 9, 1–10 (2019).
  18. Hind, C. K. et al. Evaluation of a library of FDA-approved drugs for their ability to potentiate antibiotics against multidrug-resistant gram-negative pathogens. Antimicrob. Agents Chemother. 63, 1–6 (2019).
  19. Moreau, D. et al. Drug‐induced increase in lysobisphosphatidic acid reduces the cholesterol overload in Niemann–Pick type C cells and mice. EMBO Rep. 20, 1–15 (2019).
  20. Nogueira-Recalde, U. et al. Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy. EBioMedicine 45, 588–605 (2019).
  21. Delerue, T. et al. A yeast-based screening assay identifies repurposed drugs that suppress mitochondrial fusion and mtDNA maintenance defects. DMM Dis. Model. Mech. 12, 1–9 (2019).
  22. Piddock, L. J. V. The 2019 Garrod Lecture: MDR efflux in Gram-negative bacteria – How understanding resistance led to a new tool for drug discovery. J. Antimicrob. Chemother. 74, 3128–3134 (2019).
  23. Wojtaszek, J. L. et al. A Small Molecule Targeting Mutagenic Translesion. Cell 178, 152-159.e11 (2019).
  24. Conte, M. et al. Screening for biologically annotated drugs that trigger triacylglycerol accumulation in the diatom Phaeodactylum. Plant Physiol. 177, 532–552 (2018).
  25. Ren, J. et al. Discovery of small molecule inhibitors of adenovirus by disrupting E3-19K/HLA-A2 interactions. Bioorganic Med. Chem. Lett. 28, 2837–2841 (2018).
  26. da Silva-Candal, A. et al. Clinical validation of blood/brain glutamate grabbing in acute ischemic stroke. Ann. Neurol. 84, 260–273 (2018).
  27. Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).
  28. Hall, C. J. et al. Blocking fatty acid-fueled mROS production within macrophages alleviates acute gouty inflammation. J. Clin. Invest. 128, 1752–1771 (2018).
  29. Gina Wall, Ashok K. Chaturvedi, Floyd L. Wormley, Jr., Nathan P. Wiederhold, Hoja P. Patterson, Thomas F. Patterson, J. L. L.-R. Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development. Antimicrob. Agents Chemother (2018). doi:10.1128/AAC.01084-18
  30. Fernandez, M. et al. Toxic Colors : The Use of Deep Learning for Predicting Toxicity of Compounds Merely from Their Graphic Images Introduction The discovery of new chemicals and materials plays a key role in technological innovation and. (2018). doi:10.1021/acs.jcim.8b00338
  31. Kanvatirth, P. et al. Utilisation of the Prestwick Chemical Library ® to identify drugs that 3 inhibit the growth of Mycobacteria. 1–40 (2018).
  32. Aviolat, H., Nominé, Y., Gioria, S. & Bonhoure, A. SynAggreg : A Multifunctional High-Throughput Technology for Precision Study of Amyloid Aggregation and Systematic Discovery of Synergistic Inhibitor Compounds. 1–23 (2018). doi:10.1016/j.jmb.2018.09.009
  33. Tione Buranda, Catherine Gineste, Yang Wu, Virginie Bondu, Dominique Perez, Kaylin R. Lake, Bruce S. Edwards, L. A. S. A High-Throughput Flow Cytometry Screen Identifies Molecules That Inhibit Hantavirus Cell Entry. SLAS Discov. 1 (2018).
  34. Sandra M. W. van de Wiel, D. Rudi de Waart, Ronald P. J. Oude Elferink, and S. F. J. van de G. Intestinal Farnesoid X Receptor Activation by Pharmacologic Inhibition of the Organic Solute Transporter a-b. Cell Mol Gastroenterol Hepatol 5, 223–237 (2018).
  35. Eren, R. O. et al. Development of a semi-automated image-based high-throughputdrug screening system. Front Biosci 10, 242–253 (2018).
  36. Melissa Conte, Josselin Lupette, Khawla Seddiki, Coline Meï, Lina-Juana Dolch, Valérie Gros, Caroline Barette, Fabrice Rébeillé, Juliette Jouhet, E. M. Screening for biologically annotated drugs that trigger triacylglycerol accumulation in the diatom Phaeodactylum. Plant Physiol. (2018). doi:10.1104/pp.17.01804
  37. Jung, H. et al. Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice. Diabetes Obes Metab. 1–14 (2018). doi:10.1111/dom.13284
  38. Torres, N. S. et al. Antimicrobial and Antibiofilm Activity of Synergistic Combinations of a Commercially Available Small Compound Library With Colistin Against Pseudomonas aeruginosa. 9, 1–12 (2018).
  39. Perrott, K. M., Wiley, C. D., Desprez, P. Y. & Campisi, J. Apigenin suppresses the senescence-associated secretory phenotype and paracrine effects on breast cancer cells. GeroScience 39, 161–173 (2017).
  40. Dunman. US 2017/0065540A1. (2017).
  41. Dong, J. et al. Biochimica et Biophysica Acta Bisacodyl and its cytotoxic activity on human glioblastoma stem-like cells . Implication of inositol 1 , 4 , 5-triphosphate receptor dependent. 1864, 1018–1027 (2017).
  42. O. L. M. Meijer, P. van den Biggelaar, R. Ofman , F. A. Wijburg, N. van V. High-Throughput Screen Fails to Identify Compounds That Enhance Residual Enzyme Activity of Mutant N- Acetyl- a -Glucosaminidase in Mucopolysaccharidosis Type. JIMD Rep. (2017). doi:10.1007/8904
  43. Varbanov, H. P., Kuttler, F., Banfi, D., Turcatti, G. & Dyson, J. Repositioning approved drugs for the treatment of problematic cancers using a screening approach. 1–16 (2017). doi:10.1371/journal.pone.0171052
  44. Jones, L. H. & Bunnage, M. E. Applications of chemogenomic library screening in drug discovery. Nat. Publ. Gr. 16, 285–296 (2017).
  45. Tauziede-espariat, A. et al. High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors Report High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdo. 1737–1745 (2017). doi:10.1016/j.celrep.2017.10.076
  46. Astol, A. et al. Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA E ffl ux Pump Inhibitors. J. Med. Chem. 60, 1598–1604 (2017).
  47. Jones, C. L., Njomen, E., Dexheimer, T. S. & Tepe, J. J. Small Molecule Enhancement of 20S Proteasome Activity Targets Intrinsically Disordered Proteins. ACS Chem. Biol. 12, 2240−2247 (2017).
  48. Coutard, B. et al. Toward the identi fi cation of viral cap-methyltransferase inhibitors by fl uorescence screening assay. Antiviral Res. 144, 330–339 (2017).
  49. Dunman, Paul M., Krysan, Damian J., Flaherty, D. P. Methods and composition for treating infections. (2017).
  50. Chen, W., Dong, J., Haiech, J., Kilhoffer, M. C. & Zeniou, M. Cancer stem cell quiescence and plasticity as major challenges in cancer therapy. Stem Cells Int. 2016, (2016).
  51. Smith, C. N. J. et al. Identifying ligands at orphan GPCRs : current status using structure-based approaches Tables of Links. Br. J. Pharmacol. 173, 2934–2951 (2016).
  52. Ulferts, R. et al. Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C. Antimicrob. Agents Chemother. 60, 2627–38 (2016).
  53. Torres, N. S. et al. Screening a Commercial Library of Pharmacologically Active Small Molecules Against Staphylococcus aureus Biofilms. Antimicrob. Agents Chemother. AAC.00377-16 (2016). doi:10.1128/AAC.00377-16
  54. Samantaray, S. et al. Novel cell-based in vitro screen to identify small-molecule inhibitors against intracellular replication of Cryptococcus neoformans in macrophages. Int. J. Antimicrob. Agents 48, 69–77 (2016).
  55. Chneiweiss, H., Junier, M.-P. & Etienne, V. Recycler un anti-hypertenseur pour combattre les tumeurs du cerveau. Communiqué de presse national (2016). doi:10.15252/emmm.201505421
  56. Iglesias, A., Lage, S., Cadavid, M. I., Loza, M. I. & Brea, J. Development of a Multiplex Assay for Studying Functional Selectivity of Human Serotonin 5-HT2A Receptors and Identification of Active Compounds by High-Throughput Screening. J. Biomol. Screen. (2016). doi:10.1177/1087057116644162
  57. Timiri Shanmugam, P. S. et al. Tousled kinase activator, gallic acid, promotes homologous recombinational repair and suppresses radiation cytotoxicity in salivary gland cells. Free Radic. Biol. Med. 93, 217–226 (2016).
  58. Sakano, D. et al. Dopamine D2 Receptor-Mediated Regulation of Pancreatic β Cell Mass. Stem Cell Reports 7, 95–109 (2016).
  59. Shah, E. T. et al. Repositioning ‘old’ drugs for new causes: identifying new inhibitors of prostate  cancer cell migration and invasion. Clin. Exp. Metastasis 33, 385–399 (2016).
  60. Rhim, J. heon et al. Cell type-dependent Erk-Akt pathway crosstalk regulates the proliferation of fetal neural progenitor cells. Sci. Rep. 6, 26547 (2016).
  61. Nogueira, U., Dominguez, E., Loza, M. I., Blanco, F. J. & Carames, B. Identification of novel molecules targeting cartilage aging as osteoarthritis therapeutics. Osteoarthr. Cartil. 24, S18–S19 (2016).
  62. Holler, C. J. et al. Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia. Mol. Neurodegener. 11, 46 (2016).
  63. Kang, J. et al. Improving drug discovery with high-content phenotypic screens by systematic selection of reporter cell lines. Nat Biotech 34, 70–77 (2016).
  64. Sapi, J. In Memoriam: Professor Camille-Georges Wermuth. Eur. J. Med. Chem. 108, 741 (2016).
  65. Koppel, J. et al. Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer’s disease. Alzheimer’s Dement. Transl. Res. Clin. Interv. 2, 121–130 (2016).
  66. Koschmann, J., Poroikov, V. & Wingender, K. E. Multi-omics “Upstream Analysis” of regulatory genomic regions helps identifying targets against methotrexate resistance of colon cancer. EUPROT (2016). doi:10.1016/j.euprot.2016.09.002
  67. Guetschow, E. D., Kumar, S., Lombard, D. B. & Kennedy, R. T. Identification of sirtuin 5 inhibitors by ultrafast microchip electrophoresis using nanoliter volume samples. Anal. Bioanal. Chem. 408, 721–731 (2016).
  68. Gofshteyn, J., Cárdenas, A. M. & Bearden, D. Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked agammaglobulinemia. Pediatr. Neurol. (2016). doi:10.1016/j.pediatrneurol.2016.06.014
  69. Hasegawa, S. et al. Tranilast stimulates endochondral ossification by upregulating SOX9 and RUNX2 promoters. Biochem. Biophys. Res. Commun. 470, 356–361 (2016).
  70. Arvidsson, P. I., Sandberg, K. & Forsberg-Nilsson, K. Open for collaboration: an academic platform for drug discovery and development at SciLifeLab. Drug Discov. Today 00, 1–9 (2016).
  71. Bastin, J. & Djouadi, F. Resveratrol and Myopathy. Nutrients 8, 254 (2016).
  72. Cappato, S. et al. High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva. Dis. Model. Mech. 9, 685–696 (2016).
  73. Chen, G. et al. Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy. Sci. Rep. 6, 25317 (2016).
  74. Coleman, D. T., Gray, A. L., Stephens, C. A., Scott, M. L. & Cardelli, J. A. Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-β-induced cancer-associated fibroblast differentiation. Oncotarget 7, 1–10 (2016).
  75. Druzhyna, N. et al. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine ␤ -synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon. Pharmacol. Res. 113, 18–37 (2016).
  76. Deyon-Jung, L. et al. Fragment pharmacophore-based in silico screening: A powerful approach for efficient lead discovery. Med. Chem. Commun. 7, 506–511 (2016).
  77. Cheng, H. et al. A High-Throughput Screening Platform Targeting PDLIM5 for Pulmonary Hypertension. J. Biomol. Screen. 21, 333–341 (2016).
  78. Cordeiro, O. G. et al. Integrin-alpha IIb identifies murine lymph node lymphatic endothelial cells responsive to RANKL. PLoS One 11, 1–16 (2016).
  79. Chypre, M. et al. Characterization and application of two RANK-specific antibodies with different biological activities. Immunol. Lett. 171, 5–14 (2016).
  80. Seguin, A. et al. A Yeast/Drosophila Screen to Identify New Compounds Overcoming Frataxin Deficiency. Oxid. Med. Cell. Longev. ID 565140, 1–11 (2015).
  81. Bharadwaj U., Eckols T., Kolosov M., Kasembeli T., Adam A., Torres D., Zhang X., Dobrolecki L., Wei Wei, Michael T. Lewis, Bhuvanesh Dave, Jenny C. Chang, Melissa D. Landis, Chad J. Creighton, M. A. & Mancini, and D. J. T. DRUG-REPOSITIONING SCREENING IDENTIFIED PIPERLONGUMINE AS A DIRECT STAT3 INHIBITOR WITH POTENT ACTIVITY AGAINST BREAST CANCER. Oncogene 34, 1341–1353 (2015).
  82. Diener, S. et al. Development of A Cell-Based Assay to Identify Small Molecule Inhibitors of FGF23 Signaling. Assay Drug Dev. Technol. 476–487 (2015). doi:10.1089/adt.2015.653
  83. Nguyen, P. et al. Structure − Activity Relationship Study around Guanabenz Identifies Two Derivatives Retaining Antiprion Activity but Having Lost α 2- Adrenergic Receptor Agonistic Activity. ACS Chem. Neurosci. 2014, 5, 1075–1082 (2014).
  84. Zeniou, M. et al. Chemical library screening and structure-function relationship studies identify bisacodyl as a potent and selective cytotoxic agent towards quiescent human glioblastoma tumor stem-like cells. PLoS One 1–35 (2015). doi:10.1371/journal.pone.0134793
  85. Yi, N. Y. et al. Development of a Cell-Based Fluorescence Polarization Biosensor Using Preproinsulin to Identify Compounds That Alter Insulin Granule Dynamics. Assay Drug Dev. Technol. 13, 558–569 (2015).
  86. Oprea, T. I. et al. Novel activities of select NSAID renantiomers against Rac1 and Cdc42 GTPases. PLoS One 10, 1–32 (2015).
  87. Porcu, G. et al. Clobetasol and halcinonide act as smoothened agonists to promote myelin gene expression and RxRγ receptor activation. PLoS One 10, 1–22 (2015).
  88. Rauthan, M. & Pilon, M. A chemical screen to identify inducers of the mitochondrial unfolded protein response in C. elegans. Worm 4, e1096490 (2015).
  89. Lasserre, J.-P. et al. Yeast as a system for modeling mitochondrial disease mechanisms and discovering therapies. Dis. Model. Mech. 8, 509–526 (2015).
  90. Watari, A., Hashegawa, M., Muangman, T., Yagi, K. & Kondoh, M. Use of cell-based screening to identify small-molecule compounds that modulate claudin-4 expression. Biotechnol. Lett. 37, 1177–1185 (2015).
  91. Wasko, M. J., Pellegrene, K. A., Madura, J. D. & Surratt, C. K. A role for fragment-based drug design in developing novel lead compounds for central nervous system targets. Front. Neurol. 6, 1–11 (2015).
  92. Srivastava, G. et al. Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy. Mol. Oncol. 9, 1720–1735 (2015).
  93. Takeuchi, M. & Yamamoto, T. Apoptosis induced by NAD depletion is inhibited by KN-93 in a CaMKII-independent manner. Exp. Cell Res. 335, 62–67 (2015).
  94. Stolp, Z. D. et al. A Multiplexed Cell-Based Assay for the Identification of Modulators of Pre-Membrane Processing as a Target against Dengue Virus. J. Biomol. Screen. 20, 616–26 (2015).
  95. Rybniker, J. et al. Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. Nat. Commun. 6, 1–8 (2015).
  96. Tsai, S. Y. et al. Efficient Generation of Cardiac Purkinje Cells from ESCs by Activating cAMP Signaling. Stem Cell Reports 4, 1089–1102 (2015).
  97. Teixeira-Castro, A. et al. Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain 138, 3221–3237 (2015).
  98. Preuett, B., Leeder, J. S. & Abdel-Rahman, S. Development and Application of a High-Throughput Screening Method to Evaluate Antifungal Activity against Trichophyton tonsurans. J. Biomol. Screen. 20, 1171–1177 (2015).
  99. Pedram Fatemi, R. et al. Screening for Small-Molecule Modulators of Long Noncoding RNA-Protein Interactions Using AlphaScreen. J. Biomol. Screen. 20, 1132–41 (2015).
  100. Raneri, M., Sciandrone, B. & Briani, F. A whole-cell assay for specific inhibitors of translation initiation in bacteria. J. Biomol. Screen. 20, 627–33 (2015).
  101. Ratajewski, M. et al. Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol. Lett. 232, 193–202 (2015).
  102. Park, C. Y. et al. High-throughput screening for modulators of cellular contractile force. Integr. Biol. (Camb). 7, 1–16 (2015).
  103. Ren, X.-R. et al. Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth. Breast cancer Res. 17, 1–11 (2015).
  104. Malergue, F., van Agthoven, a., Scifo, C., Egan, D. & Strous, G. J. Automation of a Phospho-STAT5 Staining Procedure for Flow Cytometry for Application in Drug Discovery. J. Biomol. Screen. 20, 416–421 (2015).
  105. Keillor, J. W., Apperley, K. Y. P. & Akbar, A. Inhibitors of tissue transglutaminase. Trends Pharmacol. Sci. 36, 32–40 (2015).
  106. Huynh, T. P. et al. Glucocorticoids Suppress Renal Cell Carcinoma Progression by Enhancing Na,K-ATPase Beta-1 Subunit Expression. PLoS One 10, e0122442 (2015).
  107. Demishtein, A., Porat, Z., Elazar, Z. & Shvets, E. Applications of flow cytometry for measurement of autophagy. Methods 75, 87–95 (2015).
  108. Divorty, N., Mackenzie, A. E., Nicklin, S. A. & Milligan, G. G protein-coupled receptor 35: An emerging target in inflammatory and cardiovascular disease. Front. Pharmacol. 6, 1–13 (2015).
  109. Grover, P., Shi, H., Baumgartner, M., Camacho, C. J. & Smithgall, T. E. Fluorescence polarization screening assays for small molecule allosteric modulators of ABL kinase function. PLoS One 10, 1–26 (2015).
  110. Ch’ng, J.-H. et al. Cell-based Screening Identifies a Rosette-Disrupting Antimalarial for the Treatment of Plasmodium falciparum Malaria Complications. Blood 1–13 (2015). doi:10.1038/srep29317
  111. Cheung, L. et al. Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen. Biochem. Pharmacol. 93, 380–388 (2015).
  112. Aggarwal, C. et al. Identification of quorum-sensing inhibitors disrupting signaling between rgg and short hydrophobic peptides in streptococci. MBio 6, 1–11 (2015).
  113. Ai, N., Wood, R. D. & Welsh, W. J. Identification of Nitazoxanide as a Group I Metabotropic Glutamate Receptor Negative Modulator for the Treatment of Neuropathic Pain: An In Silico Drug Repositioning Study. Pharm. Res. 32, 2798–807 (2015).
  114. Diener, S., Schorpp, K., Strom, T.-M., Hadian, K. & Lorenz-Depiereux, B. Development of A Cell-Based Assay to Identify Small Molecule Inhibitors of FGF23 Signaling. Assay Drug Dev. Technol. 13, 476–487 (2015).
  115. Corbel, C. et al. Tamoxifen inhibits CDK5 kinase activity by interacting with p35/p25 and modulates the pattern of tau phosphorylation. Chem. Biol. 22, 472–482 (2015).
  116. Ahn, H. J. et al. A novel A-beta-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer’s disease mice. J. Exp. Med. 211, 1049–1062 (2014).
  117. Nylén, F. et al. Boosting innate immunity: Development and validation of a cell-based screening assay to identify LL-37 inducers. Innate Immun. 20, 364–376 (2014).
  118. Discovery, D. Drug Repurposing , Repositioning and Rescue Part 1 : Overview. 57–72 (2014).
  119. Yang, Y. H. C., Vilin, Y. Y., Roberge, M., Kurata, H. T. & Johnson, J. D. Multiparameter screening reveals a role for Na+ channels in cytokine-induced β-cell death. Mol. Endocrinol. 28, 406–417 (2014).
  120. Voisset, C. et al. A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus. Dis. Model. Mech. 7, 435–444 (2014).
  121. Bret, L. Monitoring of insulin granule packaging in live cells using homoFRET-FP detection. 2–3 (2014).
  122. Röhrig, U. F. et al. Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Eur. J. Med. Chem. 84, 284–301 (2014).
  123. Sem, D. S. Sem (2014) Repurposing – Finding New Uses. 18, (2014).
  124. Normand, A., Rivi??re, E. & Renodon-Corni??re, A. Identification and characterization of human Rad51 inhibitors by screening of an existing drug library. Biochem. Pharmacol. 91, 293–300 (2014).
  125. Liu, C. et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clinical Cancer Research 20, (2014).
  126. Mech, L. D. Chemical Genetic Identification of the Histamine H1 Receptor as a Stimulator of Insulin-Induced Adipogenesis. Chem. Biol. 11, 907–913 (2014).
  127. Baell, J. & Walters, M. A. Chemical con artists foil drug discovery. Nature 513, 481–483 (2014).
  128. Zhang, M., Luo, G., Zhou, Y., Wang, S. & Zhong, Z. Phenotypic Screens Targeting Neurodegenerative Diseases. J. Biomol. Screen. 19, 1–16 (2014).
  129. Wolter, J. K. et al. Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget 5, 161–172 (2014).
  130. Wang, J. et al. A Comparative High-Throughput Screening Protocol to Identify Entry Inhibitors of Enveloped Viruses. J. Biomol. Screen. 19, 100–107 (2014).
  131. Walzl, A. et al. The Resazurin Reduction Assay Can Distinguish Cytotoxic from Cytostatic Compounds in Spheroid Screening Assays. J. Biomol. Screen. 19, 1047–1059 (2014).
  132. Theorell, J. et al. Immunomodulatory activity of commonly used drugs on Fc-receptor-mediated human natural killer cell activation. Cancer Immunol. Immunother. 63, 627–641 (2014).
  133. Tegos, G. P. et al. A high throughput flow cytometric assay platform targeting transporter inhibition. Drug Discov. Today Technol. 12, e95–e103 (2014).
  134. Patten, S. a et al. Fishing for causes and cures of motor neuron disorders. Dis. Model. Mech. 7, 799–809 (2014).
  135. Meneely, K. M. et al. Expanding the results of a high throughput screen against an isochorismate-pyruvate lyase to enzymes of a similar scaffold or mechanism. Bioorganic Med. Chem. 22, 5961–5969 (2014).
  136. Kawahara, G. et al. Dystrophic muscle improvement in zebrafish via increased heme oxygenase signaling. Hum. Mol. Genet. 23, 1869–1878 (2014).
  137. Geer, M. A. & Fitzgerald, M. C. Energetics-based methods for protein folding and stability measurements. Annu. Rev. Anal. Chem. (Palo Alto. Calif). 7, 209–28 (2014).
  138. García-Alcover, I. et al. Development of a Drosophila melanogaster spliceosensor system for in vivo high-throughput screening in myotonic dystrophy type 1. Dis. Model. Mech. 7, 1297–1306 (2014).
  139. Filgueira, C. S. et al. A screening cascade to identify ERβ ligands. Nucl. Recept. Signal. 12, 1–13 (2014).
  140. Donohue, E., Balgi, A. D., Komatsu, M. & Roberge, M. Induction of covalently crosslinked p62 oligomers with reduced binding to polyubiquitinated proteins by the autophagy inhibitor verteporfin. PLoS One 9, 1–30 (2014).
  141. Blatt, J. et al. Expanding the scope of drug repurposing in pediatrics: The Children’s Pharmacy Collaborative??? Drug Discov. Today 19, 1696–1698 (2014).
  142. Balsera, B. et al. Chalcones as positive allosteric modulators of ??7 nicotinic acetylcholine receptors: A new target for a privileged structure. Eur. J. Med. Chem. 86, 724–739 (2014).
  143. Bhuvanagiri, M. et al. 5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion. EMBO Mol. Med. 6, 1593–1609 (2014).
  144. Allali-Hassani, A. et al. A Basic Post-SET Extension of NSDs Is Essential for Nucleosome Binding In Vitro. J. Biomol. Screen. 19, 928–935 (2014).
  145. Chang, Q. et al. Cytochrome P450 2C epoxygenases mediate photochemical stress-induced death of photoreceptors. J. Biol. Chem. 289, 8337–8352 (2014).
  146. Bharadwaj, U. et al. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene 0, 1–13 (2014).
  147. Hall, C. J. et al. Repositioning drugs for inflammatory disease-fishing for new anti-inflammatory agents. Dis. Model. Mech. 7, 1069–1081 (2014).
  148. Bernardo, S. M. et al. An automated high-throughput cell-based multiplexed flow cytometry assay to identify novel compounds to target Candida albicansvirulence-related proteins. PLoS One 9, 1–11 (2014).
  149. Gutierrez, A. et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J. Clin. Invest. 124, 644–655 (2014).
  150. Aiyar, R. S. et al. Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders. Nat. Commun. 5, 1–9 (2014).
  151. Alekseev, S. et al. A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the Chemosensitization of tumor cells to platinum. Chem. Biol. 21, 398–407 (2014).
  152. Denicolaï, E. et al. Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo. Oncotarget 5, 10934–10948 (2014).
  153. Andreux, P. a et al. A method to identify and validate mitochondrial modulators using mammalian cells and the worm C. elegans. Sci. Rep. 4, 1–10 (2014).
  154. Salani, B. et al. Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II. Sci. Rep. 3, 1–8 (2013).
  155. Sadikot, T. et al. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev. Technol. 11, 478–488 (2013).
  156. Siles, S. A., Srinivasan, A., Pierce, C. G., Lopez-Ribot, J. L. & Ramasubramanian, A. K. High-throughput screening of a collection of known pharmacologically active small compounds for identification of candida albicans biofilm inhibitors. Antimicrob. Agents Chemother. 57, 3681–3687 (2013).
  157. Reipas, K. M. et al. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1). Oncotarget 4, 329–345 (2013).
  158. Shanks, E. J. Reduce, reuse, recycle: How drug repositioning is finding its niche in drug discovery. Eur. Pharm. Rev. 18, 31–34 (2013).
  159. Zeidler, U. et al. Synergy of the antibiotic colistin with echinocandin antifungals in candida species. J. Antimicrob. Chemother. 68, 1285–1296 (2013).
  160. Zeder-Lutz, G. et al. Novel surface-based methodologies for investigating GH11 xylanase-lignin derivative interactions. Analyst 138, 6889–99 (2013).
  161. Wrench, A. P., Gardner, C. L., Gonzalez, C. F. & Lorca, G. L. Identification of a Small Molecule That Modifies MglA/SspA Interaction and Impairs Intramacrophage Survival of Francisella tularensis. PLoS One 8, 1–14 (2013).
  162. Robinson, T. J. W. et al. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS One 8, (2013).
  163. Ozawa, M. et al. A cell-based screening system for influenza A viral RNA transcription/replication inhibitors. Sci. Rep. 3, 1106 (2013).
  164. Liu, M., Lin, Y. ling, Chen, X. R., Liao, C. C. & Poo, W. K. In vitro assessment of Macleaya cordata crude extract bioactivity and anticancer properties in normal and cancerous human lung cells. Exp. Toxicol. Pathol. 65, 775–787 (2013).
  165. McCormick, A. V., Wheeler, J. M., Guthrie, C. R., Liachko, N. F. & Kraemer, B. C. Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biol. Psychiatry 73, 464–471 (2013).
  166. Podolska, K., Sedlak, D., Bartunek, P. & Svoboda, P. Fluorescence-Based High-Throughput Screening of Dicer Cleavage Activity. J. Biomol. Screen. 1087057113497400 (2013). doi:10.1177/1087057113497400
  167. Kumagai, H., Suemori, H., Uesugi, M., Nakatsuji, N. & Kawase, E. Identification of small molecules that promote human embryonic stem cell self-renewal. Biochem. Biophys. Res. Commun. 434, 710–716 (2013).
  168. Kawahara, G. & Kunkel, L. M. Zebrafish based small molecule screens for novel DMD drugs. Drug Discov. Today Technol. 10, e91–e96 (2013).
  169. Jin, S. et al. An in vivo zebrafish screen identifies organophosphate antidotes with diverse mechanisms of action. J. Biomol. Screen. 18, 108–115 (2013).
  170. Kourtesi, C. et al. Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. Open Microbiol. J. 7, 34–52 (2013).
  171. Gozalbes, R. et al. Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches. Bioorganic Med. Chem. 21, 1944–1951 (2013).
  172. Gupta, V. A., Kuwada, J. Y. & Beggs, A. H. P.4.11 Developing therapies for congenital myopathies by high throughput chemical screening in ryanodine receptor 1 mutant zebrafish. Neuromuscul. Disord. 23, 762–763 (2013).
  173. Cederlund, A. et al. Label-Free Quantitative Mass Spectrometry Reveals Novel Pathways Involved in LL-37 Expression. J. Innate Immun. 365–376 (2013). doi:10.1159/000355931
  174. Audran, E. et al. A general framework to characterize inhibitors of calmodulin: Use of calmodulin inhibitors to study the interaction between calmodulin and its calmodulin binding domains. Biochim. Biophys. Acta – Mol. Cell Res. 1833, 1720–1731 (2013).
  175. Bharat, A., Blanchard, J. E. & Brown, E. D. A high-throughput screen of the GTPase activity of Escherichia coli EngA to find an inhibitor of bacterial ribosome biogenesis. J. Biomol. Screen. 18, 830–836 (2013).
  176. Chartier, A. & Simonelig, M. Animal models in therapeutic drug discovery for oculopharyngeal muscular dystrophy. Drug Discov. Today Technol. 10, e103–e108 (2013).
  177. Antoniani, D. et al. The immunosuppressive drug azathioprine inhibits biosynthesis of the bacterial signal molecule cyclic-di-GMP by interfering with intracellular nucleotide pool availability. Appl. Microbiol. Biotechnol. 97, 7325–7336 (2013).
  178. Dahlin, J. L. et al. A cell-free fluorometric high-throughput screen for inhibitors of Rtt109-catalyzed histone acetylation. PLoS One 8, (2013).
  179. Ahmad, S., Hughes, M. a, Johnson, G. L. & Scott, J. E. Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors. J. Biomol. Screen. 18, 388–399 (2013).
  180. Choulier, L. et al. Chemical library screening using a SPR-based inhibition in solution assay: Simulations and experimental validation. Anal. Chem. 85, 8787–8795 (2013).
  181. Goldman, R. C. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Tuberculosis 93, 569–588 (2013).
  182. Ding, Z. et al. Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis. J. Biomol. Screen. 17, 572–580 (2012).
  183. Walker, S. R. & Frank, D. a. Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets. Jak-Stat 1, 292–299 (2012).
  184. Zeder-Lutz, G. et al. Validation of surface plasmon resonance screening of a diverse chemical library for the discovery of protein tyrosine phosphatase 1b binders. Anal. Biochem. 421, 417–427 (2012).
  185. Villalta-Romero, F. et al. Identification of new snake venom metalloproteinase inhibitors using compound screening and rational peptide design. ACS Med. Chem. Lett. 3, 540–543 (2012).
  186. Reynolds, R. C. et al. High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv. Tuberculosis 92, 72–83 (2012).
  187. Polireddy, K. et al. A novel flow cytometric HTS assay reveals functional modulators of ATP binding cassette transporter ABCB6. PLoS One 7, 1–14 (2012).
  188. Li, Y.-J. et al. Drug-mediated inhibition of Fli-1 for the treatment of leukemia. Blood Cancer J. 2, 1–9 (2012).
  189. Lai, D. TARGETING TYROSINE KINASE INHIBITOR-INSENSITIVE CML STEM / PROGENITOR CELLS BY EFFECTIVE INHIBITION OF A NOVEL PP2A-AHI-1-BCR-ABL-JAK2 COMPLEX by Damian Lai B . Sc ., University of Ottawa , 2012 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENT. 1–93 (2012).
  190. Oprea, T. I. & Mestres, J. Drug Repurposing: Far Beyond New Targets for Old Drugs. AAPS J. 14, 759–763 (2012).
  191. Libraries, O. Drug Repurposing development strategy. 90, 1–8 (2012).
  192. Shin, J. H. et al. Suppression of autophagy exacerbates Mefloquine-mediated cell death. Neurosci. Lett. 515, 162–167 (2012).
  193. Sachlos, E. et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149, 1284–1297 (2012).
  194. Tomasini-Johansson, B. R., Johnson, I. A., Hoffmann, F. M. & Mosher, D. F. Quantitative microtiter fibronectin fibrillogenesis assay: Use in high throughput screening for identification of inhibitor compounds. Matrix Biol. 31, 360–367 (2012).
  195. Park, S. J. et al. Mitochondrial fragmentation caused by phenanthroline promotes mitophagy. FEBS Lett. 586, 4303–4310 (2012).
  196. De Chassey, B., Meyniel-Schicklin, L., Aublin-Gex, A., André, P. & Lotteau, V. New horizons for antiviral drug discovery from virus-host protein interaction networks. Curr. Opin. Virol. 2, 606–613 (2012).
  197. Gupte, J. et al. Signaling property study of adhesion G-protein-coupled receptors. FEBS Lett. 586, 1214–1219 (2012).
  198. Conesa, C. et al. Identification of Specific Pluripotent Stem Cell Death-Inducing Small Molecules by Chemical Screening. Stem Cell Rev. Reports 8, 116–127 (2012).
  199. Ahmad, S., Hughes, M. A., Yeh, L.-A. & Scott, J. E. Potential Repurposing of Known Drugs as Potent Bacterial -Glucuronidase Inhibitors. J. Biomol. Screen. 17, 957–965 (2012).
  200. Flusin, O. et al. A small molecule screen in yeast identifies inhibitors targeting protein-protein interactions within the vaccinia virus replication complex. Antiviral Res. 96, 187–195 (2012).
  201. Colliandre, L., Le Guilloux, V., Bourg, S. & Morin-Allory, L. Visual characterization and diversity quantification of chemical libraries: 2. Analysis and selection of size-independent, subspace-specific diversity indices. J. Chem. Inf. Model. 52, 327–342 (2012).
  202. Giacomotto, J., S??galat, L., Carre-Pierrat, M. & Gieseler, K. Caenorhabditis elegans as a chemical screening tool for the study of neuromuscular disorders. Manual and semi-automated methods. Methods 56, 103–113 (2012).
  203. Holmes, A. R. et al. The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. Antimicrob. Agents Chemother. 56, 1508–1515 (2012).
  204. Dos, S. et al. Biochimie Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding. Biochimie 93, 1047–1054 (2011).
  205. Manuscript, A. & Proximity, I. NIH Public Access. 4, 283–292 (2011).
  206. Sexton, J. Z. et al. Development and Implementation of a High Throughput Screen for the Human Sperm-Specific Isoform of Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDHS). Curr. Chem. Genomics 5, 30–41 (2011).
  207. Peal, D. S. et al. Novel chemical suppressors of long QT syndrome identified by an in vivo functional screen. Circulation 123, 23–30 (2011).
  208. Kumar, E. A., Charvet, C. D., Lokesh, G. L. & Natarajan, A. High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions. Anal. Biochem. 411, 254–260 (2011).
  209. Moorwood, C. et al. Drug discovery for duchenne muscular dystrophy via utrophin promoter activation screening. PLoS One 6, 1–11 (2011).
  210. Kawahara, G. & Karpf, J. Drug screening in a zebrafish model of Duchenne muscular dystrophy. Pnas 108, 5331–6 (2011).
  211. Lee, Y. J. et al. Triclabendazole protects yeast and mammalian cells from oxidative stress: Identification of a potential neuroprotective compound. Biochem. Biophys. Res. Commun. 414, 205–208 (2011).
  212. Milligan, G. Orthologue selectivity and ligand bias: Translating the pharmacology of GPR35. Trends Pharmacol. Sci. 32, 317–325 (2011).
  213. Le Guilloux, V. et al. Visual characterization and diversity quantification of chemical libraries: 1. Creation of delimited reference chemical subspaces. J. Chem. Inf. Model. 51, 1762–1774 (2011).
  214. Hubert Jr, L., Lin, Y., Dion, V. & Wilson, J. H. Topoisomerase 1 and single-strand break repair modulate transcription-induced CAG repeat contraction in human cells. Mol. Cell. Biol. 31, 3105–3112 (2011).
  215. Hundeshagen, P., Hamacher-Brady, A., Eils, R. & Brady, N. R. Concurrent detection of autolysosome formation and lysosomal degradation by flow cytometry in a high-content screen for inducers of autophagy. BMC Biol. 9, 38 (2011).
  216. Jo, Y. K. et al. ARP101, a selective MMP-2 inhibitor, induces autophagy-associated cell death in cancer cells. Biochem. Biophys. Res. Commun. 404, 1039–1043 (2011).
  217. Wermuth, C. G. Are pyridazines privileged structures? Medchemcomm 2, 935 (2011).
  218. Spitzer, M. et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol. Syst. Biol. 7, 499 (2011).
  219. Takakura, A. et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum. Mol. Genet. 20, 4143–4154 (2011).
  220. MacKenzie, A. E., Lappin, J. E., Taylor, D. L., Nicklin, S. A. & Milligan, G. GPR35 as a novel therapeutic target. Front. Endocrinol. (Lausanne). 2, 1–10 (2011).
  221. Gohil, V. M. et al. Meclizine is neuroprotective in models of Huntington’s disease. Hum. Mol. Genet. 20, 294–300 (2011).
  222. Dengler, M. A. et al. Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis. PLoS One 6, (2011).
  223. Chopra, S., Matsuyama, K., Hutson, C. & Madrid, P. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. J. Antimicrob. Chemother. 66, 1533–1536 (2011).
  224. Fonslow, B. R. et al. A High Content Screen Identifies Inhibitors of Nuclear Export of Forkhead Transcription Factors. 10, 54–56 (2011).
  225. Allen, J. A. & Roth, B. L. Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 51, 117–144 (2011).
  226. Ahmad, S. et al. A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors. Curr. Chem. Genomics 5, 13–20 (2011).
  227. Kawahara, G. et al. Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U. S. A. 108, 5331–6 (2011).
  228. Chen, M. H. et al. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. PLoS One 6, (2011).
  229. Couplan, E. et al. A yeast-based assay identifies drugs active against human mitochondrial disorders. PNAS USA 108, 11989–11994 (2011).
  230. Manuscript, A. & Proximity, I. NIH Public Access. 4, 420–429 (2011).
  231. Chigaev, A., Wu, Y., Williams, D. B., Smagley, Y. & Sklar, L. A. Discovery of Very Late Antigen-4 (VLA-4, α4β 1 integrin) allosteric antagonists. J. Biol. Chem. 286, 5455–5463 (2011).
  232. Fonslow, B. R. et al. A High Content Screen Identifies Inhibitors of Nuclear Export of Forkhead Transcription Factors. 10, 54–56 (2011).
  233. Gug, F., Oumata, N. & Blondel, M. Synthesis of Conjugates of 6-Aminophenanthridine and Guanabenz , Two Structurally Unrelated Prion Inhibitors , for the Determination of Their Cellular Targets by Affinity Chromatography. Bioconjugate Chem 21, 279–288 (2010).
  234. Zhao, P. et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol. Pharmacol. 78, 560–568 (2010).
  235. Yeyeodu, S. T., Witherspoon, S. M., Gilyazova, N. & Ibeanu, G. C. A rapid, inexpensive high throughput screen method for neurite outgrowth. Curr. Chem. Genomics 4, 74–83 (2010).
  236. Schaertl, S. et al. A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. J. Biomol. Screen.  Off. J. Soc. Biomol. Screen. 15, 478–487 (2010).
  237. Rodgers, A. D. et al. Modeling Liver-Related Adverse Effects of Drugs Using k Nearest Neighbor Quantitative Structure – Activity Relationship Method. Chem. Res. Toxicol. 23, 724–732 (2010).
  238. Shum, D. et al. High-content assay to identify inhibitors of dengue virus infection. Assay Drug Dev. Technol. 8, 553–70 (2010).
  239. Shahinas, D., Liang, M., Datti, A. & Pillai, D. R. A repurposing strategy identifies novel synergistic inhibitors of plasmodium falciparum heat shock protein 90. J. Med. Chem. 53, 3552–3557 (2010).
  240. Talele, T. T. et al. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg. Med. Chem. 18, 4630–4638 (2010).
  241. Ouertatani-Sakouhi, H. et al. Kinetic-Based High-Throughput Screening Assay to Discover Novel Classes of Macrophage Migration Inhibitory Factor Inhibitors. J. Biomol. Screen. 15, 347–358 (2010).
  242. Manuscript, A. & Syndromes, G. P. NIH Public Access. 48, 1–6 (2010).
  243. Peluso, J. & Muller, C. D. Advances in flow cytometry for drug screening. Expert Opin. Drug Discov. 5, 827–833 (2010).
  244. Kokel, D. et al. Rapid behavior-based identification of neuroactive small molecules in the zebrafish. Nat Chem Biol 6, 231–237 (2010).
  245. Langer, T. Pharmacophores in drug research. Mol. Inform. 29, 470–475 (2010).
  246. Insa, R. Drug Repositioning: Filling the Gap. Eur. Biopharm. Rev. (2010).
  247. Jadhav, A. et al. Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J. Med. Chem. 53, 37–51 (2010).
  248. Vedadi, M., Arrowsmith, C. H., Allali-Hassani, A., Senisterra, G. & Wasney, G. A. Biophysical characterization of recombinant proteins: A key to higher structural genomics success. J. Struct. Biol. 172, 107–119 (2010).
  249. Lipinski, R. J. & Bushman, W. Identification of Hedgehog signaling inhibitors with relevant human exposure by small molecule screening. Toxicol. Vitr. 24, 1404–1409 (2010).
  250. Jasenosky, L. D., Neumann, G. & Kawaoka, Y. Minigenome-based reporter system suitable for high-throughput screening of compounds able to inhibit Ebolavirus replication and/or transcription. Antimicrob. Agents Chemother. 54, 3007–3010 (2010).
  251. Leonardi, R. et al. Modulation of pantothenate kinase 3 activity by small molecules that interact with the substrate/allosteric regulatory domain. Chem. Biol. 17, 892–902 (2010).
  252. Johnson, R. M. et al. Identification of inhibitors of vacuolar proton-translocating ATPase pumps in yeast by high-throughput screening flow cytometry. Anal. Biochem. 398, 203–211 (2010).
  253. Manuscript, A. & Syndromes, G. P. NIH Public Access. 48, 1–6 (2010).
  254. Feng, R. et al. Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk. Res. 34, 917–924 (2010).
  255. Carme Mulero, M. et al. A fluorescent polarization-based assay for the identification of disruptors of the RCAN1-calcineurin A protein complex. Anal. Biochem. 398, 99–103 (2010).
  256. Barbaric, I. et al. Novel regulators of stem cell fates identified by a multivariate phenotype screen of small compounds on human embryonic stem cell colonies. Stem Cell Res. 5, 104–119 (2010).
  257. Antoniani, D., Bocci, P., MacIa̧g, A., Raffaelli, N. & Landini, P. Monitoring of diguanylate cyclase activity and of cyclic-di-GMP biosynthesis by whole-cell assays suitable for high-throughput screening of biofilm inhibitors. Appl. Microbiol. Biotechnol. 85, 1095–1104 (2010).
  258. Doughty-Shenton, D. et al. Pharmacological targeting of the mitochondrial phosphatase PTPMT1. J. Pharmacol. Exp. Ther. 333, 584–92 (2010).
  259. Gui, C., Obaidat, A., Chaguturu, R. & Hagenbuch, B. Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr. Chem. Genomics 4, 1–8 (2010).
  260. Dearmond, P. D. et al. Discovery of novel cyclophilin A ligands using an H/D exchange- and mass spectrometry-based strategy. J. Biomol. Screen. 15, 1051–62 (2010).
  261. Buckley, C. E. et al. Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects. Neuropharmacology 59, 149–159 (2010).
  262. Andrews, P. D. et al. High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. Biochem. J. 432, 21–33 (2010).
  263. Colton, C. K. et al. Identification of Translational Activators of Glial Glutamate Transporter EAAT2 through Cell-Based High-Throughput Screening: An Approach to Prevent Excitotoxicity. J. Biomol. Screen. 15, 653–662 (2010).
  264. Manuscript, A. & Leads, P. D. NIH Public Access. Tuberculosis 89, 331–333 (2010).
  265. Haynes, M. K. et al. Detection of intracellular granularity induction in prostate cancer cell lines by small molecules using the HyperCyt high-throughput flow cytometry system. J. Biomol. Screen. 14, 596–609 (2009).
  266. Haynes, M. K. et al. Detection of intracellular granularity induction in prostate cancer cell lines by small molecules using the HyperCyt high-throughput flow cytometry system. J. Biomol. Screen. 14, 596–609 (2009).
  267. Zhu, P. J. et al. Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death. Bioorganic Med. Chem. 17, 5139–5145 (2009).
  268. Sanders, B. D. et al. Identification and characterization of novel sirtuin inhibitor scaffolds. Bioorganic Med. Chem. 17, 7031–7041 (2009).
  269. Orzáez, M. et al. Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL. Bioorganic Med. Chem. Lett. 19, 1592–1595 (2009).
  270. Porotto, M. et al. Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. J. Virol. 83, 5148–5155 (2009).
  271. Norton, J. T. et al. Automated high-content screening for compounds that disassemble the perinucleolar compartment. J. Biomol. Screen. 14, 1045–1053 (2009).
  272. Mulero, M. C. et al. Inhibiting the calcineurin-NFAT (nuclear factor of activated T cells) signaling pathway with a regulator of calcineurin-derived peptide without affecting general calcineurin phosphatase activity. J. Biol. Chem. 284, 9394–9401 (2009).
  273. Langer, T., Hoffmann, R., Bryant, S. & Lesur, B. Hit finding: towards ‘smarter’ approaches. Curr. Opin. Pharmacol. 9, 589–593 (2009).
  274. MacArthur, R. et al. Monitoring Compound Integrity with cytochrome P450 assays and qHTS. Www.Sbsonline.Org 1–9 (2009). doi:10.1177/1087057109336954
  275. Wible, B. A. Incidence and specificity of drug-induced trafficking inhibition of cardiac ion channels. J. Pharmacol. Toxicol. Methods 60, 223 (2009).
  276. Iorns, E., Lord, C. J. & Ashworth, A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem. J. 417, 361–370 (2009).
  277. Huang, X. et al. Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine 2B Receptor Agonists : Implications for Drug Safety Assessment □. Mol. Pharmacol. 5, 710–722 (2009).
  278. Pyeon, D., Pearce, S. M., Lank, S. M., Ahlquist, P. & Lambert, P. F. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog. 5, (2009).
  279. Livingstone, M., Larsson, O., Sukarieh, R., Pelletier, J. & Sonenberg, N. A Chemical Genetic Screen for mTOR Pathway Inhibitors Based on 4E-BP-Dependent Nuclear Accumulation of eIF4E. Chem. Biol. 16, 1240–1249 (2009).
  280. Perne, A. et al. Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PLoS One 4, (2009).
  281. Lagunin, A. et al. Computer-aided prediction of rodent carcinogenicity by PASS and CISOC-PSCT. QSAR Comb. Sci. 28, 806–810 (2009).
  282. Kemmer, D. et al. Combining chemical genomics screens in yeast to reveal spectrum of effects of chemical inhibition of sphingolipid biosynthesis. BMC Microbiol. 9, 9 (2009).
  283. Larsen, R. S., Zylka, M. J. & Scott, J. E. A high throughput assay to identify small molecule modulators of prostatic acid phosphatase. Curr. Chem. Genomics 3, 42–9 (2009).
  284. Haiech, J., Heizmann, C. W. & Krebs, J. The 10th European symposium on calcium-binding proteins in normal and transformed cells. Biochim. Biophys. Acta 1793, 931–2 (2009).
  285. Du, L. et al. Nonaminoglycoside compounds induce readthrough of nonsense mutations. J. Exp. Med. 206, 2285–2297 (2009).
  286. Dubreuil, P. et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 4, (2009).
  287. Conn, P. J., Jones, C. K. & Lindsley, C. W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 30, 148–155 (2009).
  288. Charpentier, X. et al. Chemical genetics reveals bacterial and host cell functions critical for type IV effector translocation by Legionella pneumophila. PLoS Pathog. 5, (2009).
  289. D’Elia, M. A. et al. Probing Teichoic Acid Genetics with Bioactive Molecules Reveals New Interactions among Diverse Processes in Bacterial Cell Wall Biogenesis. Chem. Biol. 16, 548–556 (2009).
  290. Conference, I. & Sciences, P. 3 rd BBBB International Conference on Pharmaceutical Sciences. October (2009).
  291. Ananthan, S. et al. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis 89, 334–353 (2009).
  292. Hoffmann, H. H., Palese, P. & Shaw, M. L. Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Res. 80, 124–134 (2008).
  293. Ewald, J. A., Peters, N., Desotelle, J. A., Hoffmann, F. M. & Jarrard, D. F. A High-Throughput Method to Identify Novel Senescene-Inducing Compounds. J Biomol Screen 14, 853–858 (2009).
  294. Chen, S. et al. A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nat. Chem. Biol. 5, 258–265 (2009).
  295. Manuscript, A. & Formation, H. T. F. NIH Public Access. 358, 1–6 (2009).
  296. Sung, J. C. et al. Selective 5-hydroxytryptamine 2c receptor agonists derived from the lead compound tranylcypromine: Identification of drugs with antidepressant-like action. J. Med. Chem. 52, 1885–1902 (2009).
  297. Auld, D. S. et al. A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution. J. Med. Chem. 52, 1450–1458 (2009).
  298. Gozalbes, R. Pharmacophore development & NMR validation of small fragments as novel heparanase inhibitors. (2009).
  299. Hibert, M. F. French/European academic compound library initiative. Drug Discov. Today 14, 723–725 (2009).
  300. Calmels, N. et al. Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen. BMC Neurol. 9, 46 (2009).
  301. Gozalbes, R., Mosulén, S., Carbajo, R. J. & Pineda-Lucena, A. Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors. J. Comput. Aided. Mol. Des. 23, 555–569 (2009).
  302. Damoiseaux, R., Sherman, S. P., Alva, J. a, Peterson, C. & Pyle, A. D. Integrated chemical genomics reveals modifiers of survival in human embryonic stem cells. Stem Cells 27, 533–542 (2009).
  303. Haynes, M. K. et al. Detection of Intercellular Granularity Induction in Prostate Cancer Cell Lines by Small Molecules Using the HyperCyt High-Throughput Flow Cytometry System. J. Biomol. Screen. 14, 596–609 (2009).
  304. Reis, S. Dos et al. Protein Folding Activity of Ribosomal RNA Is a Selective Target of Two Unrelated Antiprion Drugs. PLoS One 3, (2008).
  305. Seyb, K. I. et al. Identification of Small Molecule Inhibitors of β–Amyloid Cytotoxicity through a Cell-based High-Throughput Screening Platform. J. Biomol. Screen. 13, 870–878 (2008).
  306. Winter, S. S. et al. High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent. J. Biomol. Screen. 13, 185–93 (2008).
  307. Wu, Z., Liu, D. & Sui, Y. Quantitative assessment of hit detection and confirmation in single and duplicate high-throughput screenings. J. Biomol. Screen. 13, 159–67 (2008).
  308. Tribouillard-Tanvier, D. et al. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One 3, (2008).
  309. Senisterra, G. a, Soo Hong, B., Park, H.-W. & Vedadi, M. Application of high-throughput isothermal denaturation to assess protein stability and screen for ligands. J. Biomol. Screen. 13, 337–42 (2008).
  310. Simeonov, A. et al. Fluorescence spectroscopic profiling of compound libraries. J. Med. Chem. 51, 2363–2371 (2008).
  311. Stoilov, P., Lin, C.-H., Damoiseaux, R., Nikolic, J. & Black, D. L. A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators. Proc. Natl. Acad. Sci. 105, 11218–11223 (2008).
  312. Nakamura, K. et al. Homogeneous time-resolved fluorescence resonance energy transfer assay for measurement of Phox/Bem1p (PB1) domain heterodimerization. J. Biomol. Screen. 13, 396–405 (2008).
  313. Patnaik, D. & Xian, J. Molecule Inhibitors of the Mitotic Kinase Haspin By High-Throughput Screening Using a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer Assay. J. Biomol. Screen. 13, 1025–1034 (2008).
  314. Krysan, D. J. & Didone, L. A High-Throughput Screening Assay for Small Molecules. 657–664 (2008). doi:10.1177/1087057108320713
  315. Lai, T. S. et al. Identification of Chemical Inhibitors to Human Tissue Transglutaminase by Screening Existing Drug Libraries. Chem. Biol. 15, 969–978 (2008).
  316. Lengsfeld, C. S. & Shoureshi, R. A. (19) United States (12). 1, (2008).
  317. Ivnitski-Steele, I. et al. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters. Assay Drug Dev. Technol. 6, 263–276 (2008).
  318. Hutchinson, D. et al. NIH Public Access. 148, 825–832 (2008).
  319. Xu, G. W. et al. A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization. Apoptosis 13, 413–422 (2008).
  320. Simeonov, A. et al. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl. Trop. Dis. 2, (2008).
  321. Simeonov, A. et al. Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction. Anal. Biochem. 375, 60–70 (2008).
  322. Johnson, R. L. et al. A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression. Anal. Biochem. 375, 237–248 (2008).
  323. Garcia-Lopez, A. et al. Genetic and chemical modifiers of a CUG toxicity model in Drosophila. PLoS One 3, (2008).
  324. Brown, R. H. & Broom, W. Assay for therapies that inhibit expression of the cytosolic CU/ZN superoxide dismutase (SOD1) gene. 1, (2008).
  325. Desbordes, S. C. et al. High-Throughput Screening Assay for the Identification of Compounds Regulating Self-Renewal and Differentiation in Human Embryonic Stem Cells. Cell Stem Cell 2, 602–612 (2008).
  326. Cascales, L. et al. Tiratricol neutralizes bacterial endotoxins and reduces lipopolysaccharide-induced TNF-α production in the cell. Chem. Biol. Drug Des. 72, 320–328 (2008).
  327. Donahue, C. P., Ni, J., Rozners, E., Glicksman, M. a. & Wolfe, M. S. Identification of Tau Stem Loop RNA Stabilizers. J. Biomol. Screen. 12, 789–799 (2007).
  328. Tsetsarkin, K. A., Vanlandingham, D. L., Mcgee, C. E. & Higgs, S. A Single Mutation in Chikungunya Virus Affects Vector Specificity and Epidemic Potential. 3, (2007).
  329. Donahue, C. P., Ni, J., Rozners, E., Glicksman, M. a. & Wolfe, M. S. Identification of Tau Stem Loop RNA Stabilizers. J. Biomol. Screen. 12, 789–799 (2007).
  330. Rezza, G. et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 370, 1840–1846 (2007).
  331. White, E. L. et al. A Novel Inhibitor of Mycobacterium tuberculosis. J. Biomol. Screen. 100–105 (2007). doi:10.1177/1087057106296484
  332. Azzaoui, K. et al. Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2, 874–880 (2007).
  333. Bender, A. et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2, 861–873 (2007).
  334. Ivey, F. D., Wang, L., Demirbas, D., Allain, C. & Hoffman, C. S. Development of a Fission Yeast-Based High-Throughput Screen to Identify Chemical Regulators of cAMP Phosphodiesterases. J. Biomol. Screen. 13, 62–71 (2007).
  335. Stuart-Kregor, P. Drug Repurposing. MSI Consult. (2007). doi:10.1016/j.drudis.2013.11.005.Toward
  336. Sprous, D. G. & Salemme, F. R. A comparison of the chemical properties of drugs and FEMA/FDA notified GRAS chemical compounds used in the food industry. Food Chem. Toxicol. 45, 1419–1427 (2007).
  337. Honson, N. S. et al. Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol. Dis. 28, 251–260 (2007).
  338. Hurtado-Guerrero, R. & van Aalten, D. M. F. Structure of Saccharomyces cerevisiae Chitinase 1 and Screening-Based Discovery of Potent Inhibitors. Chem. Biol. 14, 589–599 (2007).
  339. Fischer, H., Kansy, M., Avdeef, A. & Senner, F. Permeation of permanently positive charged molecules through artificial membranes-Influence of physico-chemical properties. Eur. J. Pharm. Sci. 31, 32–42 (2007).
  340. Crowe, A., Ballatore, C., Hyde, E., Trojanowski, J. Q. & Lee, V. M.-Y. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem. Biophys. Res. Commun. 358, 1–6 (2007).
  341. Feng, B. Y. et al. A high-throughput screen for aggregation-based inhibition in a large compound library. J. Med. Chem. 50, 2385–2390 (2007).
  342. Total, Y. Medicinal chemistry contract services achievements 2001-2007 k. 2001–2002 (2007).
  343. Chong, C. & Sullivan, D. J. New uses for old drugs. Nature 448, 645 (2007).
  344. Breger, J. et al. Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog. 3, 0168–0178 (2007).
  345. Antczak, C. et al. High-Troughput Identification of Inhibitors of Human Mitochondrial Peptide Deformylase. J. Biomol. Screen 12, 521–535 (2007).
  346. Crisman, T. J. et al. Understanding false positives in reporter gene assays: In silico chemogenomics approaches to prioritize cell-based HTS data. J. Chem. Inf. Model. 47, 1319–1327 (2007).
  347. Davis, R. E. et al. A Cell-Based Assay for I κ B α Stabilization Using A Two-Color Dual Luciferase-Based Sensor. Assay Drug Dev. Technol. 5, 85–104 (2007).
  348. Schuffenecker, I. et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 3, 1058–1070 (2006).
  349. Wermuth, C. G. Similarity in drugs: reflections on analogue design. Drug Discov. Today 11, 348–354 (2006).
  350. Wu, X. et al. Mycophenolic acid is a potent inhibitor of angiogenesis. Arterioscler. Thromb. Vasc. Biol. 26, 2414–2416 (2006).
  351. Wang, J. K. T. et al. Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform. Proc. Natl. Acad. Sci. U. S. A. 103, 10461–6 (2006).
  352. Yip, K. W. et al. Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Mol. Cancer Ther. 5, 2234–40 (2006).
  353. Discovery, A. D. General Aspects of Analogue-Based Drug Discovery. (2006).
  354. Langer, T. Prestwick Chemical. Medchemwatch 14, 98 (2012).
  355. Wermuth, C. G. Selective optimization of side activities: The SOSA approach. Drug Discov. Today 11, 160–164 (2006).
  356. Yip, K. W. et al. Benzethonium chloride: A novel anticancer agent identified by using a cell-based small-molecule screen. Clin. Cancer Res. 12, 5557–5569 (2006).
  357. Severson, W. E. et al. Development and Validation of a High-Throughput Screen for Inhibitors of SARS CoV and Its Application in Screening of a 100,000-Compound Library. J. Biomol. Screen. 12, 33–40 (2006).
  358. Ogawa, Y., Mizumoto, N., Tanaka, H., Matsushima, H. & Takashima, A. Identification of novel pharmacological activities of an antifungal agent, nystatin, to promote dendritic cell maturation. J Invest Dermatol 126, 349–353 (2006).
  359. Peters, U., Cherian, J., Kim, J. H., Kwok, B. H. & Kapoor, T. M. Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat. Chem. Biol. 2, 618–626 (2006).
  360. Monge, A., Arrault, A., Marot, C. & Morin-allory, L. Analysis of a Set of 2 . 6 Million Unique Compounds Gathered From the Libraries of 32 Chemical Providers. Analysis (2006).
  361. Monge, A., Arrault, A., Marot, C. & Morin-Allory, L. Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers. Mol. Divers. 10, 389–403 (2006).
  362. Kinobe, R. T. et al. Inhibition of the enzymatic activity of heme oxygenases by azole-based antifungal drugs. J. Pharmacol. Exp. Ther. 319, 277–284 (2006).
  363. Inglese, J. et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. U. S. A. 103, 11473–11478 (2006).
  364. Shimahara, T. Foreword. J. Physiol. 99, 73–74 (2006).
  365. Fara, D. C. et al. Integration of virtual and physical screening. Drug Discov. Today Technol. 3, 377–385 (2006).
  366. Dagher, R. et al. Use of a fluorescent polarization based high throughput assay to identify new Calmodulin ligands. Biochim. Biophys. Acta – Mol. Cell Res. 1763, 1250–1255 (2006).
  367. Broom, W. J. et al. Two approaches to drug discovery in SOD1-mediated ALS. J. Biomol. Screen. 11, 729–35 (2006).
  368. Bandyopadhyay, S. A High-Throughput Drug Screen Targeted to the 5’Untranslated Region of Alzheimer Amyloid Precursor Protein mRNA. J. Biomol. Screen. 11, 469–480 (2006).
  369. Young, S. M. High-Throughput Screening with HyperCyt(R) Flow Cytometry to Detect Small Molecule Formylpeptide Receptor Ligands. J. Biomol. Screen. 10, 374–382 (2005).
  370. Vogel, K. Multiplex binding and activity assays. 1, (2005).
  371. Tobergte, D. R. & Curtis, S. Receptor Binding Techniques. Nethods in Molecular Biology Second Edi, (2005).
  372. Setola, V., Advisor, D., Roth, B. L. & Setola, V. DISCOVERING THE MOLECULAR AND FENFLURAMINE-INDUCED CARDIOPULMONARY SIDE EFFECTS We hereby approve the dissertation of. (2005).
  373. Ray, S. S., Nowak, R. J., Brown, R. H. & Lansbury, P. T. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc. Natl. Acad. Sci. U. S. A. 102, 3639–3644 (2005).
  374. O’Connor, K. A. & Roth, B. L. Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery. Nat Rev Drug Discov 4, 1005–1014 (2005).
  375. Rao, F. V., Andersen, O. A., Vora, K. A., DeMartino, J. A. & Van Aalten, D. M. F. Methylxanthine drugs are chitinase inhibitors: Investigation of inhibition and binding modes. Chem. Biol. 12, 973–980 (2005).
  376. Razonable, R. R., Henault, M., Watson, H. L. & Paya, C. V. Nystatin induces secretion of interleukin (IL)-1??, IL-8, and tumor necrosis factor alpha by a toll-like receptor-dependent mechanism. Antimicrob. Agents Chemother. 49, 3546–3549 (2005).
  377. Mizumoto, N. et al. Discovery of novel immunostimulants by dendritic-cell – based functional screening. Blood 106, 3082–3090 (2005).
  378. Yang, B. Whole lysate Blot : MAGE-A Blot : B-actin Figure l. 1, (2005).
  379. Wible, B. A. et al. HERG-Lite??: A novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods 52, 136–145 (2005).
  380. Case, A., Ni, J., Yeh, L. A. & Stein, R. L. Development of a mechanism-based assay for tissue transglutaminase – Results of a high-throughput screen and discovery of inhibitors. Anal. Biochem. 338, 237–244 (2005).
  381. Nogrady, T. et al. Glossary of Common Terms used in Drug Discovery. Society 9, (2005).
  382. Edwards, B. S. et al. Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide. Mol. Pharmacol. 68, 1301–1310 (2005).
  383. Altar, C. A. et al. Multi-parameter high throughput screening assays (MPHTS). (2005).
  384. Bakshi, P. et al. A High-Throughput Screen to Identify Inhibitors of Amyloid beta-Protein Precursor Processing. J. Biomol. Screen. 10, 1–12 (2005).
  385. Ahn, J. S. Development of an Assay to Screen for Inhibitors of Tau Phosphorylation by Cdk5. J. Biomol. Screen. 9, 122–131 (2004).
  386. Ahn, J. S. Development of an Assay to Screen for Inhibitors of Tau Phosphorylation by Cdk5. J. Biomol. Screen. 9, 122–131 (2004).
  387. Ruebel, S. & Stuemke, M. ( 19 ) United States ( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2010 / 0041620 A1 Publication Classi ? cation 6 Weak Followup Patent Application Publication. 1, 11 (2004).
  388. Ruebel, S. & Stuemke, M. ( 19 ) United States ( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2010 / 0041620 A1 Publication Classi ? cation 6 Weak Followup Patent Application Publication. 1, (2004).
  389. Wermuth, C. G. Selective Optimization of Side Activities: Another Way for Drug Discovery. J. Med. Chem. 47, 1303–1314 (2004).
  390. Edwards, B. S., Oprea, T., Prossnitz, E. R. & Sklar, L. A. Flow cytometry for high-throughput, high-content screening. Curr. Opin. Chem. Biol. 8, 392–398 (2004).
  391. Gaud, A. et al. Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul. Disord. 14, 365–370 (2004).
  392. Doan, T. High-throughput target validation in model organisms. Drug Discov. Today TARGETS 3, 191–197 (2004).
  393. Rushton, D. N. Functional Electrical Stimulation and rehabilitation—an hypothesis. Med. Eng. Phys. 25, 75–78 (2003).
  394. Poroikov, V. V. & Filimonov, D. A. How to acquire new biological activities in old compounds by computer prediction. J. Comput. Aided. Mol. Des. 16, 819–824 (2002).
  395. Oprea, T. I. Virtual screening in lead discovery: A viewpoint. Molecules 7, 51–62 (2002).
  396. F, E., Parker, W. & Freeman, C. Review of World Facilities. 51 (1800).
  397. Quintana, J. et al. CHEMICAL BIOLOGY FOR DRUG DISCOVERY : WORKING WITH THE SPANISH CHEMICAL BIOLOGY INITIATIVE CHEMBIOBANK. 403
  398. Monge, A., Arrault, A., Marot, C. & Morin-Allory, L. Analyse de l ’ Espace Chimique de plus de 3 Millions de Molécules Destinées au Criblage Virtuel ou au Criblage à Haut Débit Problématique. Presentation
  399. Beghyn, T. et al. Have DRUG-LIKENESS Properties of Oral Drugs Evolved in the Past Decade? Poster
  400. Publicité Microsource Nature reviews.pdf.
  401. Invitrogen. Nuclear receptor proteins and assays. Nuclear Receptor Proteins and Assays Available at: www.invitrogen.com.
  402. Gioria, S. et al. Search for V1A agonist by high throughput screening using HRTF and calcium flux measurements. Poster
  403. Boa, N. Introduction to Drug Discovery Pre-20 th century medicine Willow bark and salicylic acid. Lecture 1–46
  404. Marshall, R. L. et al. New multidrug efflux inhibitors for gram-negative bacteria. MBio 11, 1–19 (2020).
  405. Mamouei, Z. et al. Alexidine Dihydrochloride Has Broad-Spectrum Activities. 3, 1–11 (2018).
  406. Hergenrother, P. J. Obtaining and screening compound collections: a user’s guide and a call to chemists. Curr. Opin. Chem. Biol. 10, 213–218 (2006).
  407. Ferreira-Ramos, A. S. et al. Approved drugs screening against the nsP1 capping enzyme of Venezuelan equine encephalitis virus using an immuno-based assay. Antiviral Res. 163, 59–69 (2019).
  408. , Rose E. Jeeves. 1–40 (2018).
  409. López, L. C. et al. Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation. Int. J. Mol. Sci. 17, (2016).
  410. Jiang, X. et al. A Novel Application of Furazolidone: Anti-Leukemic Activity in Acute Myeloid Leukemia. PLoS One 8, 1–9 (2013).
  411. Blatt, J. & Corey, S. J. Drug repurposing in pediatrics and pediatric hematology oncology. Drug Discov. Today 18, 4–10 (2013).
  412. Mangat, C. S. & Brown, E. D. Known Bioactive Small Molecules Probe the Function of a Widely Conserved but Enigmatic Bacterial ATPase, YjeE. Chem. Biol. 15, 1287–1295 (2008).
  413. Zotchev, S. B. et al. Rational design of macrolides by virtual screening of combinatorial libraries generated through in silico manipulation of polyketide synthases. J. Med. Chem. 49, 2077–2087 (2006).
  414. Kuhn, I. et al. Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD+ catabolizing enzyme. Bioorganic Med. Chem. 18, 7900–7910 (2010).
  415. Vidalain, P. & Lucas-hourani, M. Activation de la réponse innée antivirale par des inhibiteurs de la biosynthèse des pyrimidines Les surprises d ’ un criblage. 30, 98–104 (2015).
  416. Fattahi, F. et al. Deriving human ENS lineages for cell therapy and drug discovery in Hirschsprung disease. Nature 531, 105–9 (2016).
  417. Nath, A. K. et al. PTPMT1 inhibition lowers glucose through succinate dehydrogenase phosphorylation. Cell Rep. 10, 694–701 (2015).
  418. Chakraborty, M., Sellier, C., Ney, M., Pascal, V. & Charlet-berguerand, N. Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy. 1, 1–12 (2018).
  419. Dey, R. & Chen, L. In search of allosteric modulators of α7-nAChR by solvent density guided virtual screening. J. Biomol. Struct. Dyn. 28, 695–715 (2011).
  420. Palandri, A., Martin, E., Russi, M. & Rera, M. Identification of cardioprotective drugs by medium-scale in vivo pharmacological screening on a Drosoph ila cardiac model of Friedreich ’ s Keywords : Summary statement : Abstract : (2018). doi:10.1242/dmm.033811
  421. Wang, Y. et al. Glucocorticoid compounds modify smoothened localization and hedgehog pathway activity. Chem. Biol. 19, 972–982 (2012).
  422. Bergamo, A., Riedel, T., Dyson, P. J. & Sava, G. Preclinical combination therapy of the investigational drug NAMI-A+ with doxorubicin for mammary cancer. Invest. New Drugs 33, 53–63 (2015).
  423. Foundation, S. et al. RE(ACT) Congress. 9-12 March 2016, Barcelona. 3rd International Congress on Research of Rare and Orphan Diseases. 9th to 12th March 2016. Crowne Plaza Barcelona – Fira Center, Barcelona, Spain: Abstracts. Mol. Syndromol. 6, 304–335 (2016).
  424. Urbaniak, M. D. et al. Identification of novel inhibitors of UDP-Glc 4???-epimerase, a validated drug target for african sleeping sickness. Bioorganic Med. Chem. Lett. 16, 5744–5747 (2006).
  425. Ekins, S., Williams, A. J., Krasowski, M. D. & Freundlich, J. S. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov. Today 16, 298–310 (2011).
  426. Voisset, C., García-Rodríguez, N., Birkmire, A., Blondel, M. & Wellinger, R. E. Using yeast to model calcium-related diseases: Example of the Hailey-Hailey disease. Biochim. Biophys. Acta – Mol. Cell Res. 1843, 2315–2321 (2014).
  427. Pytel, D. et al. Enzymatic Characterization of ER Stress-Dependent Kinase, PERK, and Development of a High-Throughput Assay for Identification of PERK Inhibitors. J Biomol screen 2, 1024–1034 (2014).
  428. Ekins, S. et al. Open drug discovery for the Zika virus. F1000Research 5, 150 (2016).
  429. Prado, S. et al. Bioavailable inhibitors of HIV-1 RNA biogenesis identified through a Rev-based screen. Biochem. Pharmacol. 107, 14–28 (